

CASE 1-32709A

FILING BY "EXPRESS MAIL" UNDER 37 CFR 1.10

EV 483669445 US  
Express Mail Label Number

October 5, 2005  
Date of Deposit

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE PCT NATIONAL STAGE APPLICATION OF  
HOFSTEENGE ET AL.

INTERNATIONAL APPLICATION NO: PCT/EP03/11139

FILED: 8 OCTOBER 2003

U.S. APPLICATION NO: 10/530,457

35 USC §371 DATE: Not Yet Known

FOR: ASSAYS FOR C-MANNOSYLTRANSFERASE

**Mail Stop: Amendment**

Commissioner for Patents  
PO Box 1450  
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Sir:

Applicants believe this paper is being filed before the mailing date of a first Office Action on the merits. Under 37 C.F.R. §1.97(b)(3), no fees are required. If a fee is deemed to be required, the Commissioner is hereby authorized to charge such fee to Deposit Account No. 19-0134.

In accordance with 37 C.F.R. §1.56, applicants wish to call the Examiner's attention to the references cited on the attached form(s) PTO-1449.

The asterisked references were cited in the International Search Report. Since copies of said references were forwarded by the International Bureau, only copies of the non-asterisked references are enclosed.

Some of the listed references were cited in a search report in a corresponding British application. Copies of these references and the search report are enclosed herewith.

The Examiner is requested to consider the foregoing information in relation to this application and indicate that each reference was considered by returning a copy of the initialed PTO 1449 form(s).

Respectfully submitted,


Novartis  
Corporate Intellectual Property  
One Health Plaza, Building 104  
East Hanover, NJ 07936-1080  
(617) 871-3346

  
\_\_\_\_\_  
John T. Prince  
Attorney for Applicants  
Reg. No. 43,019

Date: October 5, 2005

**INFORMATION DISCLOSURE CITATION**

(Use several sheets if necessary)



ATTY. DOCKET NO.  
1-32709A  
APPLICATION NO.  
10/530,457  
APPLICANT  
HOFSTEENGE ET AL.  
FILING DATE  
APRIL 5, 2005

Group

**U.S. PATENT DOCUMENTS**

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						
	AL						

**FOREIGN PATENT DOCUMENTS**

		DOCUMENT NUMBER	DATE	OFFICE	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
	AM	EP 0272603					<input type="checkbox"/>	<input type="checkbox"/>
	AN	EP 1260591					<input type="checkbox"/>	<input type="checkbox"/>
	AO						<input type="checkbox"/>	<input type="checkbox"/>
	AP						<input type="checkbox"/>	<input type="checkbox"/>
	AQ						<input type="checkbox"/>	<input type="checkbox"/>

\*Cited in the International Search Report.

**OTHER DOCUMENTS** (Including Author, Title, Date, Pertinent pages, Etc.)

AR	*Keusch, et al., "C-mannosylation of Cell Surface Glycoproteins", Glycobiology, Vol. 12, p. 674 (2002)
AS	Hendershot, et al., "An Efficient Assay for Dolichyl Phosphate-mannose", Analyst Biochem., Vol. 307, pp. 273-79 (2002)
AT	Krieg, et al., "C-mannosylation of Human Rnase 2", J. Biol. Chem., Vol. 272, pp. 26687-92 (1997)

**EXAMINER**

**DATE CONSIDERED**

\*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

## INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DOCKET NO.  
1-32709A  
APPLICATION NO.  
10/530,457  
APPLICANT  
HOFSTEENGE ET AL.  
FILING DATE  
APRIL 5, 2005

Group

EXAMINER  
INITIAL

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

DA	Krieg, et al, "Recognition Signal for C-mannosylation", Mol. Biol. Cell, Vol. 9, pp. 301-9 (1998)
DB	Doucey, et al., "Protein C-mannosylation Is Enzyme-catalysed and Uses Dolichy-phosphate-mannose as a Precursor", Mol. Biol. Cell, Vol. 9, pp. 291-300 (1998)
DC	Asselbergs, et al. "A Two-plasmid system for Transient Expression of cDNAs in Primate Cells", Analytical Biochem., Vol. 209, pp. 327-31 (1993)
DD	Bos, et al., "Role of Complement in Graft Rejection after Organ Transplantation", Trans. Medicine Rev., Vol. 16, pp. 251-64 (2002)
DE	Bruckner, et al., "Glycosyltransferase Activity of Fringe Modulates Notch-Delta Interactions", Nature, Vol. 406, pp. 411-15 (2000)
DF	de Beer, et al., "The Hexopyranosyl Residue that Is C-glycosidically Linked to the Side Chain of Tryptophan-7 in Human RNase Us Is a-Mannopyranose", Biochem., Vol. 34, pp. 11785-89 (1995)
DG	Ellgaard, et al., "ER Quality Control: Towards an Understanding at the Molecular Level", pp. 431-37
DH	Furmanek, et al., "Protein C-mannosylation: Facts and Questions", Acta Biochemica Polonica, Vol. 47, pp. 781-89 (2000)
DI	Hartmann, et al., "Properdin, the Positive Regulator of Complement, Is Highly C-mannosylated", J. Bio. Chem., Vol. 275, pp. 28569-74 (2000)
DJ	Hofsteenge, et al., "The Four Terminal Components of the Complement System Are C-mannosylated on Multiple Tryptophan Residues", J. Biol. Chem., Vol. 274, pp. 32786-94 (1999)
DK	Krieg, et al., "Recognition Signal for C-mannosylation of Trp-7 in RNase 2 Consists of Sequence Trp-x-xTrp", Mol. Biol. of the Cell, Vol. 9, pp. 301-9 (1998)
DL	Krieg, et al., "C-mannosylation of Human RNase 2 Is an Intracellular Process Performed by a Variety of Cultured Cells", J. of Biol. Chem., Vol. 272, pp. 26687-92 (1997)
DM	Luhn, et al, "The Gene Defective in Leukocyte Adhesion Deficiency II Encodes a Putative GDP-fucose Transporter", Nature Gen., Vol. 28, pp. 69-81 (2001)
DN	Moloney, et al., "Fringe Is a Glycosyltransferase that Modifies Notch", Nature, Vol. 406, pp. 369-75 (2000)

EXAMINER

DATE CONSIDERED


\*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

FORM PTO-1449  
(REV. 7-85)U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICE**INFORMATION DISCLOSURE CITATION**

(Use several sheets if necessary)

ATTY. DOCKET NO.  
1-32709A  
APPLICATION NO.  
10/530,457  
APPLICANT  
HOFSTEENGE ET AL.  
FILING DATE  
APRIL 5, 2005

Group

EXAMINER  
INITIAL**OTHER DOCUMENTS** (Including Author, Title, Date, and Pertinent pages, Etc.)

DA	Monsinjon, et al., "Complement and Its Implications in Cardiac Ischemia/Reperfusion: Strategies to Inhibit Complement", Fund. & Clin. Pharmacology, Vol. 15, pp. 293-306 (2001)
DB	Newton, et al., "Expression and Characterization of Recombinant Human Eosinophil-derived Neurotoxin and Eosinophil-derived Neurotoxin-anti-transferrin Receptor sFv", J. Biol. Chem., Vol. 269, pp. 26739-45 (1994)
DC	
DD	
DE	
DF	
DG	
DH	
DI	
DJ	
DK	
DL	
DM	
DN	

**EXAMINER****DATE CONSIDERED**

\*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.